Study to Assess the Long-term Safety of Lenvatinib Monotherapy, a Lenvatinib Combination Regimen, or a Comparator Treatment Arm to Cancer Participants in Eisai Sponsored Lenvatinib Trials
- Registration Number
- NCT03477175
- Lead Sponsor
- Eisai Inc.
- Brief Summary
This study will be conducted to assess the long-term safety of study drug(s) in participants who are enrolled in Eisai-sponsored lenvatinib studies.
- Detailed Description
This is an open-label extension study to roll-over eligible participants from Eisai-sponsored lenvatinib studies. The participants may roll-over no sooner than the primary completion dates in their parent study or after all study data for the primary outcome measure have been collected for the parent study. The parent study is defined as the Eisai-sponsored lenvatinib clinical study in which the participant was receiving lenvatinib either as monotherapy or as combination therapy or was receiving any other comparator therapy. The participant can be enrolled in the current study for the purpose of long-term safety data collection if all the selection criteria for the current study are met. The intention is that the participant will not be without study drug during the transition from the parent study to the rollover study.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 40
It is required for all participants currently participating in other lenvatinib studies to meet the following eligibility criteria.
- Provide signed written informed consent for the roll-over study
- Currently enrolled in an Eisai-sponsored lenvatinib clinical study and still receiving at least one of the study drugs from that protocol
- Currently deriving clinical benefit from at least one of the study drug(s) as determined by the investigator
- Must be able and willing to comply with the current roll-over protocol requirements
- Continued ability to swallow and retain orally administered study drug(s)
- Does not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowels
- Women of childbearing potential and men with reproductive potential (if specified by the parent study) must be willing to continue to use highly effective methods of contraception as per local practices of standard of care during the period of the study
- Women of childbearing potential must have a negative serum pregnancy test at the time of transition to the study and before continuing study drug(s)
- Permanent discontinuation of all study drug(s) in the parent study due to toxicity or disease progression and without clinical benefit
- Receiving any prohibited medication(s) as described in the parent study
- Any unresolved toxicity that meets the criteria for study drug(s) discontinuation or withdrawal criteria from the parent study at the time of transition to this study
- Uncontrolled diabetes, hypertension or other medical conditions at the time of transition to the roll-over study that may interfere with assessment of toxicity
- Pregnant or lactating female
- Any serious and/or unstable pre-existing medical condition, psychiatric disorder or other conditions at the time of transition to the roll-over study that could interfere with participant's safety in the opinion of the investigator
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Cohort A : Lenvatinib E7080 The roll-over eligible participants from Eisai-sponsored lenvatinib studies who received lenvatinib monotherapy or who crossed over from a comparator arm to receive lenvatinib monotherapy in their parent study will continue to receive lenvatinib monotherapy. Cohort B: Lenvatinib plus Comparator drug Comparator Drug The roll-over eligible participants from Eisai-sponsored lenvatinib studies who received lenvatinib combination therapy or who crossed over from a comparator arm to receive lenvatinib combination therapy in their parent study will continue to receive lenvatinib combination therapy. Cohort C: Comparator drug Comparator Drug The roll-over eligible participants from Eisai-sponsored lenvatinib studies who received comparator treatment in their parent study will continue to receive comparator treatment, with exception of participants receiving placebo. For China only: The roll-over eligible participants from Eisai-sponsored lenvatinib studies who received comparator treatment in their parent study will continue to receive sorafenib, with exception of participants receiving placebo. Cohort B: Lenvatinib plus Comparator drug E7080 The roll-over eligible participants from Eisai-sponsored lenvatinib studies who received lenvatinib combination therapy or who crossed over from a comparator arm to receive lenvatinib combination therapy in their parent study will continue to receive lenvatinib combination therapy.
- Primary Outcome Measures
Name Time Method Number of Participants With Any Treatment-Emergent Serious Adverse Events (TESAEs) Up to 58.8 months in current study A treatment-emergent adverse events (TEAE) was defined as an adverse event (AE) that emerged during the treatment in the current roll-over study, having been absent prior to the time the participant signed the current roll-over study informed consent form (ICF), or re-emerged during treatment in the current roll-over study after having been present but resolved before signing the ICF or worsened in severity during treatment in the current roll-over study relative to the pre-ICF state, when the AE was continuous. A serious adverse event (SAE) was any untoward medical occurrence that at any dose: resulted in death; life threatening condition; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; was a congenital anomaly/birth defect or was medically important due to other reasons than the mentioned criteria.
Number of Participants With Any Non-Serious Treatment-Emergent Adverse Events (TEAEs) Up to 58.8 months in current study A TEAE was defined as an AE that emerged during the treatment in the current roll-over study, having been absent prior to the time the participant signed the current roll-over study in ICF, or re-emerged during treatment in the current roll-over study after having been present but resolved before signing the ICF or worsened in severity during treatment in the current roll-over study relative to the pre-ICF state, when the AE was continuous. A non-serious TEAE was any AE that was not considered a serious adverse event.
Number of Participants With Treatment-Related TEAEs Up to 58.8 months in current study A TEAE was defined as an AE that emerged during the treatment in the current roll-over study, having been absent prior to the time the participant signed the current roll-over study ICF, or re-emerged during treatment in the current roll-over study after having been present but resolved before signing the ICF or worsened in severity during treatment in the current roll-over study relative to the pre-ICF state, when the AE was continuous. Related TEAE was defined as AE with causal relationship between the study drug and the TEAE.
Number of Participants With Any TEAE Up to 58.8 months in current study A TEAE was defined as an AE that emerged during the treatment in the current roll-over study, having been absent prior to the time the participant signed the current roll-over study ICF, or re-emerged during treatment in the current roll-over study after having been present but resolved before signing the ICF or worsened in severity during treatment in the current roll-over study relative to the pre-ICF state, when the AE was continuous.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (28)
Harbor UCLA Medical Center
🇺🇸Torrance, California, United States
Northwestern University
🇺🇸Chicago, Illinois, United States
Eisai trial site 2
🇩🇪Essen, Germany
Samsung Medical Center - PPDS
🇰🇷Seoul, Korea, Republic of
Centrum Onkologii Instytut im.Marii Sklodowskiej Curie-Oddzial w Gliwicach
🇵🇱Gliwice, Poland
Cliniques Universitaires Saint-Luc
🇧🇪Bruxelles, Brussels, Belgium
UZ Antwerpen
🇧🇪Edegem, Antwerpen, Belgium
Chulalongkorn University
🇹🇭Pathum Wan, Krung Thep Maha Nakhon, Thailand
National Cancer Center
🇰🇷Goyang-si, Gyeonggido, Korea, Republic of
Het Nederlands Kanker Instituut Antoni Van Leeuwenhoek Ziekenhuis
🇳🇱Amsterdam, Noord-Holland, Netherlands
The Alfred Hospital
🇦🇺Melbourne, Australia
Karmanos Cancer Institute
🇺🇸Detroit, Michigan, United States
Affiliated Hospital of Guilin Medical University
🇨🇳Guilin, Guangxi, China
Harbin Medical University Cancer Hospital
🇨🇳Haerbin, Heilongjiang, China
Sun Yat-sen University, Cancer Center
🇨🇳Guangzhou, Guangdong, China
Henan Cancer Hospital
🇨🇳Zhengzhou, Henan, China
Union Hospital Tongji Medical College Huazhong University of Science and Technology
🇨🇳Wuhan, Hubei, China
Jiangsu Cancer Hospital
🇨🇳Nanjing, Jiangsu, China
Hunan Cancer Hospital
🇨🇳Changsha, Hunan, China
The First Hospital of Jilin University
🇨🇳Changchun, Jilin, China
No.10 People of Shanghai
🇨🇳Shanghai, Shanghai, China
Nanjing First Hospital
🇨🇳Nanjing, Jiangsu, China
West China School of Medicine/West China Hospital, Sichuan University
🇨🇳Chengdu, Sichuan, China
Tianjin Medical University Cancer Institute & Hospital
🇨🇳Tianjin, Tianjin, China
Zhejiang Cancer Hospital
🇨🇳Hangzhou, Zhejiang, China
Eisai trial site 1
🇩🇪Würzburg, Germany
Azienda Ospedaliero Universitaria Pisana
🇮🇹Pisa, Toscana, Italy
Institutul National de Endocrinologie "C. I. Parhon"
🇷🇴Bucharest, Romania